Matinas Biopharma Holdings, Inc. · AMEX:MTNB
Matinas Biopharma — Investor Presentation (November 2023)
31 slides from Matinas Biopharma's investor presentation, Nov 20, 2023
Slide 1: Matinas BioPharma Corporate Presentation November 2023
MATINAS BIOPHARMA Corporate Presentation November 2023 www.matinasbiopharma.com NYSE American: MTNB
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains “forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, cash flow and other sta
Slide 3: Matinas Investment Thesis: LNC Delivery Unlocks Therapeutic Value
Matinas Investment Thesis: LNC Delivery Unlocks Therapeutic Value _ > Intracellular delivery Lipid Nanocrystals > Oral administration > Less toxicity (LNCs) » Targeting beyond the liver MAT2203 Clinical Validation Pipeline Products of LNC Capabilities and Opportunities S > * Oral Amphotericin B - wi
Slide 4: Internal and External Pipeline
Internal and External Pipeline Program Indication Discovery Preclinical Phase 1 Phase 2 Phase 3 Collaborators ‘MAT2203 Invasive Aspergillosis LNC-AmphotericinB_ (UPA) Phase 3 Ready [NIH)) (oral) LNC Internal platform programs Undisclosed Undisclosed (small oligonucleotides) LNC-ASO LNC-Fab fragment
Slide 5: Lipid Nanocrystals (LNCs): A Clinically Validated Intracellular Delivery Platform
Lipid Nanocrystals (LNCs): A Clinically Validated Intracellular Delivery Platform Phosphatidy!- serine bilayer Hydrophobic drug Phosphatidylserine Stable, phospholipid- calcium crystalline nanocrystals 50-500 nm Delivery of small molecules and small oligonucleotides » Successful delivery of small mo
Slide 6: Phosphatidylserine Enables Cellular Targeting and Intracellular Delivery
Phosphatidylserine Enables Cellular Targeting and Intracellular Delivery Targeting Stressed Cells Externalize PS Normally, PS With injury, is confined to PS moves from the inner the inner layer layer to the outer layer (facing cytosol) of the cell membrane i Inf y or g 2 2 i 2 ¢ FI ie Z B =] PHOSPHA
Slide 7: LNCs - Differentiated from Liposomes and LNPs
LNCs - Differentiated from Liposomes and LNPs Liposome LNP LNC + Aqueous interior surrounded 7 3 by bilayer * lonizable lipid complexing + Non-aqueous bilayer Structure + Drug can be encapsulated in with MRNA + Highly stable ° aqueous core or bilayer + Non-aqueous interior + Efficient intracellular
Slide 8: MAT2203: Oral Amphotericin B
MAT2203 Oral Amphotericin B Clinical Validation of LNC Delivery MATINAS
Slide 9: The Growing Threat of Invasive Fungal Infections (IFIs)
The Growing Threat of Invasive Fungal Infections (IFls) WIRED ‘The Bate Agi the Fungal Apoatpse Sones eee Nature Reviews Microbiology 2022 Tackling the emerging threat of antifungal resistance to human health WHO fungal priority pathogens list to guide research, development and health action Wall St
Slide 10: MAT2203: Unlocking the Full Potential of Amphotericin B
MAT2203: Unlocking the Full Potential of Amphotericin B Innate Amphotericin B lV Amphotericin B — Unlocked Characteristics Limitations = Potential POTENT - Only available through Available systemically Y 1) 1) @ broad-spectrum fungicidal Minimal drug-drug interactions Low propensity for resistance A
Slide 11: EnACT: Phase 2 Clinical Validation of Safety and Efficacy
EnACT: Phase 2 Clinical Validation of Safety and Efficacy EnACT Clinical Data in Cryptococcal Meningitis Validates the Use of the LNC Platform to Enable Oral Administration and Overcome Toxicity ( (| @)) eo e @ Exceeded the primary All patients completing No breakthrough endpoint threshold induction
Slide 12: Results of EnACT Published in Highly-Regarded Peer-Reviewed Journal
Results of EnACT Published in Highly-Regarded Peer-Reviewed Journal Clinical Infectious Diseases ry a) h Ivma ‘SIDSA._. GN Oral Lipid Nanocrystal Amphotericin B for Cryptococcal Meningitis: A Randomized Clinical Trial David R. Boulware,“ Mucunguzi Atukunda,** Enock Kagimu,? Abdu K. Musubire,’ Andrew
Slide 13: MAT2203 Expanded Access Program - Targeted Treatment of IFIs Throughout the Body
MAT2203 Expanded Access Program - Targeted Treatment of IFls Throughout the Body Sinus ‘Mucor nidicola Pansinusitis Lung Aspergillus calidoustus Pulmonary aspergillosis Probable fusarium species Fusarium pneumonia Skin Prototheca wickerhamii Fusarium falciforme Skin infection Skin graft Fusarium spe
Slide 14: MAT2203 Expanded Access/Compassionate Use Program
MAT2203 Expanded Access/Compassionate Use Program Demonstrated Efficacy in Treatment of Patients with Limited Treatment Options 13 patients with no other treatment options are currently receiving or have completed treatment with MAT2203 — Notable Healthcare Institutions: NIH, University of Michigan,
Slide 15: Compassionate Use - Recovery from IV Ampho-B Kidney Toxicity with MAT2203
Compassionate Use - Recovery from IV Ampho-B Kidney Toxicity with MAT2203 A 38 y/o female with systemic lupus erythematosus on chronic hydroxychloroquine and prednisone presented with a progressively enlarging wound on her left foot. 712022: Patient admited twice for dysgeusia, 05/2022: nausea, vomi
Slide 16: High Unmet Medical Need in Treatment of Invasive Aspergillosis (IA)
6 High Unmet Medical Need in Treatment of Invasive Aspergillosis (IA) * Invasive aspergillosis (IA) is a serious and life-threatening invasive fungal infection that occurs primarily in severely immunocompromised patients with hematological malignancies and transplant recipients = ~15,000 new cases p
Slide 17: MAT2203 Regulatory Strategy
MAT2203 Regulatory Strategy ¢ Near-term development strategy refined to narrow initial target indication: treatment of invasive aspergillosis in patients with limited treatment options (azole-intolerant, azole-resistant, or not effectively managed with an azole) — Register leveraging LPAD pathway —
Slide 18: Proposed Phase 3 Study Design in Invasive Aspergillosis (IA)
Proposed Phase 3 Study Design in Invasive Aspergillosis (IA) » To demonstrate that initial treatment with IV LAMB followed by step-down to oral MAT2203 is superior to lV LAMB followed by SoC treatment in adult patients with Invasive Aspergillosis (IA) who are unable to receive treatment with a mold-
Slide 19: MAT2203 Value Proposition
MAT2203 Value Proposition ORAL LACK OF rm oral step-down BMPHOTERICIN'E ADMINISTRATION NEPHROTOXICITY with a potent fungicidal age Phase 2 . . LCM Cryptococcal Meningitis ) v ® - Treatment of Other IFis aa i (Proof of Concept) (Limited: 0 ) is) * Prophylaxis Near-Term Development Strategy: Focused s
Slide 20: LNCs Beyond MAT2203
LNCs Beyond MAT2203 Efficient and Safe Delivery of Small Oligos MATINAS
Slide 21: LNC Experience to Date
LNC Experience to Date Jn Vivo Animal Studies Cystic fibrosis mouse model Amika [So Mucocutaneous ASO candidiasis Amphotericin - 8 BALB/c mouse flu model _Flu protein Job's syndrome, NIH iRNA Vulvovaginal Candidiasis Amphotericin - 8 Infection Mouse SARS-CoV-2 model Remdesivir (Wo) Phase 2 ss HIV/ c
Slide 22: LNC-Remdesivir: In vivo Efficacy Against SARS-CoV-2
LNC-Remdesivir: /n vivo Efficacy Against SARS-CoV-2 In Mice Infected With Sars-COV-2, Oral LNC-Remdesivir Mitigated Weight Loss, Improved Congestion Scores, and Reduced Viral Lung Titers (Beginning On Day 2) @ ciead 110 5 108 2 4 ge é = 8 a a 2 Bs @ ee & 108 § 90 s 8 3 bo © © Pe o 2 0 8 10° . & 1 °
Slide 23: LNC-formulated Small Oligos Show Strong Uptake in Phagocytes
LNC-formulated Small Oligos Show Strong Uptake in Phagocytes Support Role in Impacting Inflammation 99.9 975 Percent of 1° 94.5 cells with ang intracellular. : small oligos 108 63.4 60 39.9 40 : [ 38 5 03 Ss 02 00 © 03 Neutrophits Monocytes moc poe 20 ug/mLLNC 812 ng/ml. CySlabeled SIRNA cargo Bitim
Slide 24: In vitro Tumor Cell Inhibition with LNC Docetaxel Formulations
/n vitroTumor Cell Inhibition with LNC Docetaxel Formulations 3 LNC Formulations Demonstrated Significantly Better Tumor Cell Inhibition Than Unformulated Drug RATIONALE AND NEXT STEPS MSL -S-MMS3 e-MMS4 —e—Taxo! * LNC-Docetaxel program also provides 90 80 insight into tumor uptake of LNCs — Foundat
Slide 25: In-vivo Therapeutic Efficacy of Oral Docetaxel LNCs in a Murine Syngeneic Melanoma Model
In-vivo Therapeutic Efficacy of Oral Docetaxel LNCs in a Murine Syngeneic Melanoma Model 410 B16F10 tumor els Day6 Ar J vatentecontl th no Day 14 Female CS7B1/6 mice —— Docetaxel 0.15 mg/mouse ion day and day 10 . (n=40) Injection Begin kx OraILNC-ooetael-high dose - 0.5 ma/ay5-13 Sacrifice ) | | Or
Slide 26: In vitro Dose-Dependent Knockdown of IL-17A in Murine T Cells
/n vitro Dose-Dependent Knockdown of IL-17A in Murine T Cells STUDY DESIGN LNC Formulation of an RNAi * Small oligo: 18-25 nucleotides * EL4 cells: 200k/well 400 + IL6 (0.3 ug/ml) stimulation * Treat and evaluate @ 24 hrs IL-17A (pg/ml) looking at IL-17 protein production 150 KEY RESULTS IL-17 Knock
Slide 27: Unlocking the Full Potential of the LNC Platform
Unlocking the Full Potential of the LNC Platform Matinas is working internally and with third parties to broaden its pipeline of LNC-based therapeutics FUTURE I UNDER EVALUATION Potential Therapeutic Applications INFECTION » Anti-infectives © Antivirals * INFLAMMATION » Autoimmune diseases PROVEN Or
Slide 28: Rapid Evolution of Platform Sets Stage for Active Q4
Rapid Evolution of Platform Sets Stage for Active Q4 Q4 2022 Q1 2023 Q2 2023 93 2023 04.2023 General Platform | Infection EnacT presentation (ID Week} Expended Access case presentations EnACT publication Pipeline Presentation and Potential Expanded Access Late Breaker Oral Abstract (ID week October
Slide 29: Expanding LNC Intellectual Property Portfolio
Expanding LNC Intellectual Property Portfolio Continuingly increasing our patent suite to increase protection and exclusivity ao MAT2203 potentially Global Platform IP Recent patent entitled to 12+ years base protection out to applications based on of exclusivity 2037 with 20 patents formulation wor
Slide 30: Experienced Leadership Team
Experienced Leadership Team EXECUTIVE TEAM Jerome D. Jabbour, J.D. Chief Executive Officer James Ferguson, M.D. Chief Medical Officer AMGEN stazenecs > Teticines Corea ‘Thomas Hoover, MBA Chief Business Officer SEMEN *Ssunovon Keith Kucinski, CPA, MBA Chief Financial Officer PAR barr ‘Theresa Matkov
Slide 31: Near-Term Milestones- Setup for Strong Close to 2023
Near-Term Milestones- Setup for Strong Close to 2023 Matinas Investment Thesis Y Q4 - FDA Meeting and Feedback on MAT2203 Phase 3 Invasive Aspergillosis LPAD Study Y Q4 - 1D Week MAT2203 Pipeline Presentation and Potential Compassionate Use Late Breaker Oral Abstract Financial Summary Vv Q4 - snvivo
Matinas BioPharma Holdings — Investor Presentation (November 2023) on 6ix